Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Midatech Pharma Plc ‘very excited’ to take GNP technology into trials

Tuesday, November 15, 2016 4:57
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Midatech Pharma (LON:MTPH Nasdaq:MTP) is to take its gold-plated nanoparticle technology forward into trials as a treatment for advanced liver cancer.

Chief executive Jim Phillips tells Proactive: ”This is the first time that we’ve been able to advance a targeted chemotherapy in a way that’s not been possible until now, so it’s very exciting for us.”

”It’s the first targeted chemotherapy that we have developed completely in-house and will be our first one, we hope into patients”, Phillips added.

Compound MTR104 has been selected to start a formal new drug-enabling programme during 2017, with human studies scheduled for 2018.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.